Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Catriona Jamieson, UCSD
Program Theme: TBA
- TBA
Speaker Profile
PMWC PIONEER AWARD
Drove checkpoint blockade into practice (incl. ipilimumab)
M.D., Ph.D., PHARMD, FAACR, FAIO, FASCO, Director, Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine
Biography
Dr. Jedd D. Wolchok is a pioneering figure in cancer immunotherapy, renowned for his instrumental role in the development and approval of groundbreaking treatments for melanoma. His leadership in clinical trials led to the FDA approval of ipilimumab, the first checkpoint inhibitor immunotherapy, and the combination of nivolumab and ipilimumab, establishing new standards of care for advanced melanoma patients. Throughout his career, Dr. Wolchok has been at the forefront of translational research, focusing on novel immunotherapeutic agents and the mechanisms of immune response to cancer. His laboratory has significantly contributed to understanding the tumor microenvironment and developing strategies to overcome resistance to immunotherapy. His contributions have been recognized with numerous prestigious awards, including the His work continues to shape the future of cancer treatment, emphasizing the potential of immunotherapy to provide durable control across various cancer types.
Talk
Clinical uses of cancer immunotherapy
We will explore innovative immunotherapeutic strategies to modulate the immune response to cancer as well as to better understand the mechanistic basis for sensitivity and resistance to currently available immunotherapies.
Speaker Profile
Ph.D., CEO, Atropos Health
Biography
Dr. Brigham Hyde is CEO and co-founder of Atropos Health since August 2022. He provided funding and support for Atropos Healths official launch in late 2020. Hyde has a significant track record of building businesses in the health tech and real-world data (RWD) space and previously served as President of Data Analytics at Eversana. Prior to that role, Hyde served as a healthcare partner at the AI venture fund Symphony AI, where he led the investment in, co-founded, and operated Concert AI, an oncology RWD company valued at $1.9B. Hyde held previous roles as Chief Data Officer at Decision Resources Group, which was acquired by Clarivate for $900M in 2020. He has also served on the Global Data Science Advisory Board for Janssen, as a research faculty at MIT Media Lab, and served as adjunct faculty at Tufts Medical School.
